| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/09/2005 | WO2005023096A3 Methods and compositions for ultrasound imaging of apoptosis |
| 06/09/2005 | WO2005020876A3 Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
| 06/09/2005 | WO2005009356A3 Method for the preparation of controlled release formulations |
| 06/09/2005 | WO2005009276A3 Microbial cellulose wound dressing |
| 06/09/2005 | WO2005002510A3 Deployable multifunctional hemostatic agent |
| 06/09/2005 | WO2004105737A3 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents |
| 06/09/2005 | WO2004101756A3 Ovr110 antibody compositions and methods of use |
| 06/09/2005 | WO2004099307A3 Nanocylinder-modified surfaces |
| 06/09/2005 | WO2004035629A8 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 06/09/2005 | US20050124862 Thyroid hormone analogs and methods of use |
| 06/09/2005 | US20050124743 Hybrid system for solubilizing pharmaceutically active substances in polymer matrices |
| 06/09/2005 | US20050124697 Topical applying to skins; sunscreen agents; anticancer agents; using arylpropionic acid |
| 06/09/2005 | US20050124589 New use, pharmaceutical preparations as well as a process for their production |
| 06/09/2005 | US20050124578 Aqueous compositions containing metronidazole |
| 06/09/2005 | US20050124571 Exposure a suspension of active agents such as viral vector and microparticles to condition which results in greater efficiency; injecting mixture, then removal of microparticles |
| 06/09/2005 | US20050124569 chemically synthesized double stranded siNA against Chemokine CXC Motif, Receptor 4 (CXCR4); modulate chemokine receptors such as CXCR4 and CXCR7A; use to inhibit viral infection (e.g., HIV), inflammatory diseases |
| 06/09/2005 | US20050124568 Moderating gene expression; mixture of small nucleic acids |
| 06/09/2005 | US20050124567 Apoptosis; controlling central nervous system disorders |
| 06/09/2005 | US20050124566 Using small nucleic acid as moderators of gene expression |
| 06/09/2005 | US20050124546 Oligopeptide lyophilisate, their preparation and use |
| 06/09/2005 | US20050124537 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 06/09/2005 | US20050124069 Transfection reagents |
| 06/09/2005 | US20050124061 Derived from nicotine, linked to t cell epitope; antibodies; for treatment of cocaine addiction; immunization |
| 06/09/2005 | US20050123897 Controlling flux of penetrants across adaptable, semipermeable porous barrier by enlarging applied dose per area; drug delivery kits, patches |
| 06/09/2005 | US20050123627 an alkalizing agent; and multiparticulates containing about 20% to 75% azithromycin, and, about 25% to 80% of a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate and a poloxamer |
| 06/09/2005 | US20050123625 Compositions for treatment of viral-induced skin lesions and methods of using same |
| 06/09/2005 | US20050123618 Method of producing micro-capsules for the sustained release of drugs |
| 06/09/2005 | US20050123613 Used for intravenous transfusion; compatibility with tissues, have no toxicity or side effect, have no harmful stimulation, have no immunogenicity |
| 06/09/2005 | US20050123611 Has an active material substantially homogeneously dispersed throughout the particles and wherein the active material is capable of being released from particles |
| 06/09/2005 | US20050123610 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof |
| 06/09/2005 | US20050123609 Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
| 06/09/2005 | US20050123608 Preparation of powder agglomerate |
| 06/09/2005 | US20050123606 Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| 06/09/2005 | US20050123605 Anticancer agents; prevent forming blood vessels; removal blockage |
| 06/09/2005 | US20050123604 Comprise 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid; cyclooxygenase-2 dependent disorder |
| 06/09/2005 | US20050123601 Envelope of film forming, water soluble polymer enclosing a core; mixture containing plasticizer and acid; food, drugs, oral hygiene, cosmetics |
| 06/09/2005 | US20050123600 Compositions and methods for drug delivery using pH sensitive molecules |
| 06/09/2005 | US20050123599 Oil-in-water adjuvant of water, MF59, a steroid and a saponin; vaccine |
| 06/09/2005 | US20050123598 Phospho-amino acid end groups interact with receptors on antigen-presenting cells; for treatment of T-cell mediated disorders (autoimmune conditions), inflammatory disorders, neurodegenerative disorders, and endothelial dysfunction disorders; liposomes; kits |
| 06/09/2005 | US20050123597 Releasable linkage and compositions containing same |
| 06/09/2005 | US20050123593 Chondroitin sulfate, keratinsulphate, heparin, heparin sulfate and dermatan sulfate encapsulated in a bilayer forming dipalmitoylphosphatidylcholine phospholipid; dosage; osteoarthritis |
| 06/09/2005 | US20050123592 Pharmaceutical compositions and methods for insulin treatment |
| 06/09/2005 | US20050123588 Hemostatic agent ( microporous polysaccharide microspheres) and a therapeutic agent deposited on chitosan a hemostatic substrate for controlling bleeding caused by surgery or traumatic injuries |
| 06/09/2005 | US20050123577 Use of prostaglandin EP-3 receptor antagonists as cosmetic agents for attenuating, reducing or stopping the loss of head hair and other hairs |
| 06/09/2005 | US20050123576 Mupirocin compositions for topical use, an improved process of making same and methods of using same |
| 06/09/2005 | US20050123575 Heating, cooling, reheating and recooling a mixture containing hard fat while stirring; cosmetics, cosmeceutical, pharmaceutical; second temperature is lower than the congelation temperature of the mixture; hard fat is a mixture of triester of glycerin with caprylic, capric and stearic acids |
| 06/09/2005 | US20050123563 Lipoparticles comprising proteins, methods of making, and using the same |
| 06/09/2005 | US20050123549 E.g. an antibody that binds the CA6 glycotope conjugated to a cytotoxic agent such as a maytansine; kit with instructions for treating cancer and tumors |
| 06/09/2005 | US20050123548 Modified peptides as therapeutic agents |
| 06/09/2005 | US20050123537 Treating cancer and other angiogenic diseases |
| 06/09/2005 | US20050123536 Treatment of immunological disorders using anti-dc30 antibodies |
| 06/09/2005 | US20050123533 Prodrugs activated by targeted catalytic proteins |
| 06/09/2005 | US20050123523 Immunostimulatory nucleic acid molecules |
| 06/09/2005 | US20050123505 polysaccharides grafted with polyesters, used for encapsulation of drugs, to form time-release agents |
| 06/09/2005 | US20050123501 addition polymerization of zwitterionic monomers, under molecular weight control, to form polymers having low polydispersity, used for drug delivery |
| 06/09/2005 | US20050123491 Composition and method for treating onychomycosis |
| 06/09/2005 | US20050123482 Temperature activated gaseous liposomes; therapy drug delivery; accumulating in cancer and disease tissue |
| 06/09/2005 | US20050123481 Radio-opaque polymeric biomaterials |
| 06/09/2005 | DE10353310A1 Verwendung einer Lösung mit mindestens einem nichtionischen Tensid Use of a solution with at least one non-ionic surfactant |
| 06/09/2005 | CA2548202A1 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 06/09/2005 | CA2547382A1 Method and system for rapid transdermal administration |
| 06/09/2005 | CA2547165A1 Mutated anti-cd22 antibodies and immunoconjugates |
| 06/09/2005 | CA2547034A1 Anticarcinoma antibodies and uses thereof |
| 06/09/2005 | CA2546677A1 Pharmaceutical formulations for the sustained release of interferons and therapeutic applications thereof |
| 06/09/2005 | CA2546675A1 Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications |
| 06/09/2005 | CA2546622A1 Use of isogenic drug-resistant cell lines to determine the sequence of chemotherapeutic drug treatment |
| 06/09/2005 | CA2546616A1 Gene delivery mediated by liposome-dna complex with cleavable peg surface modification |
| 06/09/2005 | CA2545575A1 Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof |
| 06/09/2005 | CA2545473A1 Macromolecular drug complexes having improved stability and therapeutic use of the same |
| 06/09/2005 | CA2540621A1 Enhanced drug delivery |
| 06/08/2005 | EP1538210A2 Dna-based vaccination of fish by immersion |
| 06/08/2005 | EP1538202A2 Production of human alpha-galactosidase A |
| 06/08/2005 | EP1538166A1 Biodegradable hyaluronic acid derivative and composition containing micelles made therefom |
| 06/08/2005 | EP1538164A1 RGD targeting moiety its production and use |
| 06/08/2005 | EP1538157A2 Isolation and use of SH3 binding peptides |
| 06/08/2005 | EP1538156A1 Versatile linker compound and ligand, and method for preparation thereof |
| 06/08/2005 | EP1537877A2 Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| 06/08/2005 | EP1537876A1 Erythropoietin solution formulation |
| 06/08/2005 | EP1537868A1 Antifungal medicinal compositions |
| 06/08/2005 | EP1537859A2 Azithromycin dosage forms with reduced side effects |
| 06/08/2005 | EP1537858A1 Drug delivery vehicles and uses thereof |
| 06/08/2005 | EP1537857A1 Mupirocin compositions for topical use, a process of making same and uses thereof |
| 06/08/2005 | EP1537207A2 Recombinant colstridium neurotoxin fragments |
| 06/08/2005 | EP1536850A1 Medical device having hydration inhibitor |
| 06/08/2005 | EP1536845A1 Wound dressing materials comprising complexes of anionic polysaccharides with silver |
| 06/08/2005 | EP1536844A2 Preparation of m(co)3-complexes by solid phase techniques via metal assisted cleavage from the solid support |
| 06/08/2005 | EP1536840A2 Formulation for inwardly transferring nucleic acids into eucaryotic cells |
| 06/08/2005 | EP1536838A1 Conjugated hydroxyalkyl starch allergen compounds |
| 06/08/2005 | EP1536837A1 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 06/08/2005 | EP1536836A2 Topical emulsion- gel composition comprising diclofenac sodium |
| 06/08/2005 | EP1536835A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 06/08/2005 | EP1536828A2 Methods of delivery of exogenous proteins to the cytosol and uses thereof |
| 06/08/2005 | EP1536822A1 Stable pharmaceutical composition comprising erythropoietin |
| 06/08/2005 | EP1536814A2 Antibodies to non-shed muc1 and muc16, and uses thereof |
| 06/08/2005 | EP1536807A2 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 06/08/2005 | EP1536801A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| 06/08/2005 | EP1536793A1 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases |
| 06/08/2005 | EP1536791A1 Sustained-release tablet comprising reboxetine |
| 06/08/2005 | EP1536775A1 Compositions comprising hmg-coa reductase inhibitor |
| 06/08/2005 | EP1536774A1 Taste masked dosage forms and processes for their preparation |